Pressmeddelanden från Newbury Pharmaceuticals

Newbury Pharmaceuticals publishes its annual report for 2024/2025

Newbury Pharmaceuticals AB has published its annual report for the 2024/2025 financial year.

MFN • 10 Dec 20:30

Kallelse till årsstämma i Newbury Pharmaceuticals AB

Notice of annual general meeting

MFN • 09 Dec 16:15

Nordic Market Update

MFN • 18 Nov 13:50

Newbury Pharmaceuticals appoints its founder Karl Karlsson as new CEO

The company today announced that Karl Karlsson, currently Executive Chairman of the Board, has been appointed CEO of Newbury Pharmaceuticals...

MFN • 11 Nov 13:15

Newbury Pharmaceuticals year-end report September 2024 – August 2025

MFN • 29 Oct 08:00

Newbury Pharmaceuticals Secures Generic Approval for Mirtazapin Newbury

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Mirtazapin Newbury 15, 30 and 45 mg tablets in...

MFN • 24 Oct 08:30

Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Ivermectin Newbury 10 mg/g cream in Denmark as...

MFN • 23 Oct 14:30

Newbury Pharmaceutical, CEO, Lars Minor, will present the company at Økonomisk Ugebrev's Life Science Conference on 24 September 2025 in Copenhagen.

Newbury Pharmaceutical, CEO, Lars Minor, will present the company at Økonomisk Ugebrev's Life Science Conference on 24 September 2025 in Cop...

MFN • 23 Sep 08:30

Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Melatonin Newbury 2 mg prolonged-release table...

MFN • 11 Aug 10:00

Newbury Pharmaceuticals interim report September 2024 – May 2025

MFN • 09 Jul 08:00

Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 16 million and extends the existing SEK 15 million loan agreement

Newbury Pharmaceuticals AB (“Newbury” or the “Company”) carries out a directed share issue of approximately 6.

MFN • 28 Apr 09:21

Newbury Pharmaceuticals Secures Generic Approval for Pazopanib Newbury

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pazopanib Newbury tablets in Sweden as the fir...

MFN • 16 Apr 13:30

Newbury Pharmaceuticals interim report September 2024 – February 2025

MFN • 09 Apr 08:00

Newbury Pharmaceuticals expands its portfolio with four new products

Newbury Pharmaceuticals is strengthening its distribution partnership with an existing collaborator by adding four already registered produc...

MFN • 19 Mar 11:00

Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Macitentan Newbury in Denmark as the first cou...

MFN • 14 Mar 08:30

Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Pomalidomide Newbury in Denmark as the first c...

MFN • 24 Jan 10:00

Newbury Pharmaceuticals interim report September 2024 – November 2024

MFN • 24 Jan 08:00

Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Bosutinib Newbury in Norway as the first count...

MFN • 22 Jan 09:00

Newbury Pharmaceuticals Secures Generic Approval for Azelastine + Fluticasone nasal spray

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Azelastine + Fluticasone nasal spray in Norway...

MFN • 15 Jan 14:00

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 15 January 2025.

MFN • 15 Jan 11:23

Newbury Pharmaceuticals publishes its annual report for 2023/2024

Newbury Pharmaceuticals AB has published its annual report for the 2023/2024 financial year.

MFN • 11 Dec 2024 19:30

Kallelse till årsstämma i Newbury Pharmaceuticals AB

Notice of annual general meeting

MFN • 11 Dec 2024 09:30

Newbury Pharmaceuticals Secures Generic Approval for Buspiron

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Buspiron tablets in Sweden.

MFN • 28 Oct 2024 10:00

Newbury Pharmaceuticals year-end report September 2023 – August 2024

MFN • 23 Oct 2024 11:15

Newbury Pharmaceuticals AB has agreed to extend the existing 15 MSEK loan agreement.

Newbury has agreed to a 12-month extension of the loan agreement announced on the 18th of September, 2023.

MFN • 30 Sep 2024 09:00

Strong Quarterly Sales Announcement from Newbury Pharmaceuticals

Newbury Pharmaceuticals AB is pleased to announce higher than expected sales growth in Quarter 4 (June-Aug 2024) reaching sales of approxima...

MFN • 27 Sep 2024 15:56

Newbury Pharmaceuticals Secures Approval for Varenicline in Sweden

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Varenicline Newbury in Sweden.

MFN • 23 Sep 2024 13:00

Regulatory Filing for Teduglutide

Newbury has through one of its partners initiated a DCP filing for Teduglutide on Day-1 following the expiry of Data Exclusivity.

MFN • 13 Sep 2024 11:30

Extraordinary general meeting in Newbury Pharmaceuticals AB (publ)

Extraordinary general meeting in Newbury Pharmaceuticals AB (publ) (the ”Company”) was held on 31 July 2024.

MFN • 31 Jul 2024 10:04

NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEWBURY PHARMACEUTICALS AB

Swedish version follow after the English version.

MFN • 12 Jul 2024 09:30

Newbury Pharmaceuticals interim report September 2023 – May 2024

MFN • 10 Jul 2024 08:00

Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Liraglutide pre-filled pen in Denmark as the f...

MFN • 20 Jun 2024 13:00

Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Dalbavancin 500mg Powder for...

MFN • 18 Jun 2024 08:45

Newbury Pharmaceuticals interim report September 2023 – February 2024

MFN • 10 Apr 2024 08:00

Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 19 million

Newbury Pharmaceuticals AB (“Newbury” or the “Company”) carries out a directed share issue of approximately 4.

MFN • 04 Mar 2024 08:15

Newbury Pharmaceuticals receives international sales order valued at 8.8 million SEK

Newbury Pharmaceuticals is delighted to announce the receipt of a sales order, scheduled for delivery in May 2024, from an customer located ...

MFN • 22 Feb 2024 08:30

Nintedanib Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Nintedanib Newbury 100 & 150 mg soft capsules tablets in ...

MFN • 17 Jan 2024 10:00

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 10 January 2024.

MFN • 10 Jan 2024 11:20

Newbury Pharmaceuticals interim report September 2023 – November 2023

MFN • 10 Jan 2024 08:00

Newbury Pharmaceuticals publishes its annual report for 2022/2023

Newbury Pharmaceuticals AB has published its annual report for the 2022/2023 financial year.

MFN • 13 Dec 2023 23:00

Kallelse till årsstämma i Newbury Pharmaceuticals AB

Notice of annual general meeting

MFN • 08 Dec 2023 13:00

Newbury Pharmaceuticals is strengthening its portfolio with Melatonin Extended Release 2 mg

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Melatonin Extended Release 2...

MFN • 20 Oct 2023 08:00

Newbury Pharmaceuticals year-end report September 2022 – August 2023

MFN • 11 Oct 2023 08:00

Newbury Pharmaceuticals has entered into a partnership granting access to 6 registered products.

Newbury has signed a contract with Amarox Limited to represent and distribute their products in Sweden and Denmark.

MFN • 06 Oct 2023 13:00

Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Levodopa/Benserazide tablets...

MFN • 22 Sep 2023 10:00

Newbury Pharmaceuticals AB has successfully signed a 15 MSEK loan agreement

Newbury has secured immediate funding represented by a loan of 15 MSEK from independent private investors.

MFN • 18 Sep 2023 14:00

Newbury gains access to the Nordic hospital market with a new strategic partnership for prescription medicine

A new strategic partnership with a global pharmaceutical company underpins the strategic ambition of being a local champion and provides New...

MFN • 23 Aug 2023 08:00

Desmopressin Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Desmopressin Newbury 60, 120 & 240 mcg sublingual tablets...

MFN • 19 Jul 2023 11:30

Newbury Pharmaceuticals sets financial goals for 2024 and 2028

Newbury Pharmaceuticals AB today announces its five-year goals for the business.

MFN • 16 Jun 2023 09:42

Newbury Pharmaceuticals interim report September 2022 – May 2023

MFN • 14 Jun 2023 08:00

Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14

Newbury Pharmaceuticals has previously announced that the interim report for the period September 2022 – May 2023 will be published on July ...

MFN • 13 Jun 2023 17:40

Newbury to present at Redeye Growth Day 2023

On June 1st at 10:00 CEO, Lars Minor will discuss the latest developments in Newbury Pharmaceuticals at Redeye Growth Day 2023.

MFN • 25 May 2023 13:00

Pirfenidone Newbury approved by the Norwegian Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Pirfenidone Newbury 267 & 801 mg film-coated tablets in N...

MFN • 12 May 2023 08:30

Solifenacin/Tamsulosin Newbury approved by the Norwegian Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Solifenacin/Tamsulosin Newbury 6 mg/0,4 mg modified relea...

MFN • 02 May 2023 11:00

Newbury Pharmaceuticals interim report September 2022 – February 2023

MFN • 12 Apr 2023 08:00

Lapatinib Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lapatinib Newbury 250 mg film-coated tablets in Sweden as...

MFN • 24 Mar 2023 11:45

Dimethyl Fumarate Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Dimethyl Fumarate Newbury 120 & 240 mg hard capsule in Sw...

MFN • 06 Mar 2023 14:30

Newbury Pharmaceuticals is strengthening its portfolio with Buspirone tablets

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Buspirone tablets.

MFN • 02 Feb 2023 07:45

ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 11 January 2023.

MFN • 11 Jan 2023 11:45

Newbury Pharmaceuticals interim report September 2022 – November 2022

MFN • 11 Jan 2023 08:00

International sales orders for 2023

Newbury Pharmaceuticals has received orders for international markets covering shipments during 2023 totalling a value of app.

MFN • 09 Jan 2023 08:00

Fampridine Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Fampridine Newbury 10 mg prolonged-release tablets in Swe...

MFN • 27 Dec 2022 10:00

Newbury Pharmaceuticals publishes its annual report for 2021/2022

Newbury Pharmaceuticals AB has published its annual report for the 2021/2022 financial year.

MFN • 14 Dec 2022 08:00

Kallelse till årsstämma i Newbury Pharmaceuticals AB

Notice of annual general meeting

MFN • 08 Dec 2022 12:00

Redeye will host two events with Newbury Pharmaceuticals in December

Following the recent publication of its analysis of Newbury Pharmaceuticals, Redeye will host two events where Newbury Pharmaceuticals, CEO,...

MFN • 06 Dec 2022 07:00

Newbury expands its portfolio with two ready to launch products

Newbury Pharmaceuticals is pleased to announce the expansion of its portfolio with Daptomycin and Linezolid with already granted Marketing A...

MFN • 23 Nov 2022 09:30

Newbury will participate at the RedEye Life Science Day – 24th November 2022

Lars Minor, CEO, Newbury Pharmaceuticals presents at Redeye Life Science Day 2022.

MFN • 22 Nov 2022 08:00

Teriflunomide Newbury approved by the Norwegian Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Teriflunomide Newbury 14 mg film-coated divisible tablets...

MFN • 01 Nov 2022 08:30

Newbury Pharmaceuticals year-end report September 2021 – August 2022

MFN • 13 Oct 2022 08:00

Newbury Pharmaceuticals management has purchased shares in the company

MFN • 07 Sep 2022 13:15

Newbury Pharmaceuticals engages Pareto Securities to reduce spread in share price

MFN • 05 Sep 2022 15:00

Newbury Pharmaceuticals expands the team with a Head of Business Development

Newbury Pharmaceuticals is pleased to announce the appointment of Mrs.

MFN • 02 Aug 2022 14:30

Newbury Pharmaceuticals interim report September 2021 – May 2022

“Besides sales uptake in both Norway and Sweden, we continue to invest in new license opportunities as well as ongoing regulatory filings of...

MFN • 06 Jul 2022 08:00

Newbury Pharmaceuticals is strengthening its portfolio with Teriparatide injection in pre-filled pen

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Teriparatide injection pre-f...

MFN • 09 Jun 2022 07:15

Newbury Pharmaceuticals is strengthening its portfolio with two new products

MFN • 26 Apr 2022 08:00

Newbury Pharmaceuticals interim report September 2021 – February 2022

“It has been another strong Quarter with significant milestones.

MFN • 13 Apr 2022 08:00

Sunitinib Newbury approved by the Danish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Sunitinib Newbury in Denmark as the first country in a Sc...

MFN • 29 Mar 2022 16:30

Lenalidomide Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Lenalidomide Newbury in Sweden as the first country in a ...

MFN • 07 Mar 2022 08:45

Commercialisation of Icatibant Newbury

Newbury Pharmaceuticals AB has successfully entered the Swedish and Norwegian market by making its first product available to patients and p...

MFN • 21 Feb 2022 07:15

Newbury on business focus and strategy (Video)

Newbury Pharmaceuticals’ CEO has joined an interview with Västra Hamnen Corporate Finance where the topic was Newbury’s choice of business f...

MFN • 15 Feb 2022 11:00

Newbury Pharmaceuticals AB publishes prospectus regarding offering of newly issued shares prior to listing application on Nasdaq First North Growth Market

The Board of Directors of Newbury Pharmaceuticals AB (“Newbury” or “the Company”) decided on January 10th, 2022, with the support of the aut...

MFN • 11 Jan 2022 10:00

Newbury Pharmaceuticals interim report September 2021 – November 2021

MFN • 21 Dec 2021 17:15

Newbury Pharmaceuticals signs strategic agreement for treatment of short bowel syndrome in the Nordics and strengthens the strategic focus on rare diseases

Newbury Pharmaceuticals is pleased to announce the agreement of an exclusive license to commercialize its own brand of Teduglutide 5mg pre-f...

MFN • 14 Dec 2021 12:45

Newbury Pharmaceuticals is strengthening its oncology portfolio

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the oncology portfolio with the addition of Lapatinib.

MFN • 10 Dec 2021 14:00

Newbury Pharmaceuticals is strengthening its portfolio and strategic focus

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with additional seven (7) oncology products; Nint...

MFN • 21 Oct 2021 11:30